Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis

Table 1 Characteristics of the patients

Age (yr)	60 (19-78)
Gender (male/female)	60/82
AST (IU/L)	37.5 (14-328)
ALT (IU/L)	36 (10-388)
γ-GTP (IU/L)	29 ( 7-259)
ALP (IU/L)	217 ( 97-556)
Total bilirubin (mg/dL)	0.7 (0.1-2.1)
Albumin (g/dL)	3.96 ± 0.36
Hemoglobin (g/dL)	13.4 ± 1.8
Platelet (× 104/mm3)	15.9 ± 5.5
PT-INR	1.04 ± 0.07

AST: Aspartate aminotransferase; ALT: Alanine transaminase; ALP: Alkaline phosphatase; PT-INR: Prothrombin time international normalized ratio.

Table 2 Characteristics of the patients (F0-F3 vs F4), (F0-F2 vs F3-F4) and (F0-F1 vs F2-F4)

	F0-F3(n = 115)	F4(n = 27)	P value	F0-F2(n = 86)	F3-F4(n = 56)	P value	F0-F1(n = 61)	F2-F4(n = 81)	P value
Age (yr)	60 (19-78)	62 (23-78)	NS	60 (19-78)	62 (23-78)	NS	60 (19-78)	62 (23-78)	NS
Gender (male/female)	48/67	12/15	NS	31/55	29/37	NS	25/36	35/46	NS
AST (IU/L)	35 (14-195)	50 (20-328)	< 0.001	32 (14-175)	46 (20-328)	< 0.001	32 (14-104)	42 (18-328)	< 0.001
ALT (IU/L)	38 (10-388)	47 (10-310)	< 0.05	31.5 (10-388)	48 (10-310)	< 0.01	31 (11-388)	46 (10-310)	< 0.01
γ-GTP (IU/L)	25 ( 7-183)	50 (12-259)	< 0.001	22 ( 7-183)	42.5 (12-259)	< 0.0001	22 ( 8-183)	36 ( 7-259)	< 0.01
ALP (IU/L)	207 ( 97-490)	267 (133-556)	< 0.001	186 (97-465)	275 (133-556)	< 0.0001	207 ( 97-465)	258 (101-556)	< 0.001
Total bilirubin (mg/dL)	0.7 (0.1-1.6)	0.7 (0.3-2.1)	NS	0.7 (0.1-1.6)	0.8 (0.3-2.1)	NS	0.7 (0.1-1.6)	0.7 (0.3-2.1)	NS
Albumin (g/dL)	4.02 ± 0.31	3.70 ± 0.43	< 0.001	4.03 ± 0.32	3.84 ± 0.37	< 0.01	4.05 ± 0.31	3.89 ± 0.38	< 0.01
Hemoglobin (g/dL)	13.5 ± 1.7	12.8 ± 2.0	NS	13.5 ± 1.8	13.3 ± 1.7	NS	13.7 ± 1.7	13.2 ± 1.8	NS
Platelet (× 104/mm3)	16.5 ± 5.3	13.2 ± 5.9	< 0.001	17.2 ± 5.2	13.8 ± 5.5	< 0.001	17.2 ± 4.8	14.9 ± 5.9	< 0.05
PT-INR	1.03 ± 0.05	1.08 ± 0.06	< 0.001	1.02 ± 0.05	1.07 ± 0.06	< 0.001	1.02 ± 0.05	1.05 ± 0.08	< 0.05

AST: Aspartate aminotransferase; ALT: Alanine transaminase; ALP: alkaline phosphatase; PT-INR: Prothrombin time international normalized ratio.

Table 3 Glycated albumin/glycated hemoglobin ratio for the detection of cirrhosis (F4), severe fibrosis (F3-F4) and significant fibrosis (F2-F4) (%)

	F4	F0-F3	F3-F4	F0-F2	F2-F4	F0-F1
GA/HbA1c > 3.0	16/27 (59.3)	34/115 (29.6)	28/56 (50.0)	22/86 (25.6)	36/81 (44.4)	14/61 (23.0)
GA/HbA1c ≤ 3.0	11/27 (40.7)	81/115 (70.4)	28/56 (50.0)	64/86 (74.4)	45/81 (55.6)	47/61 (77.0)

GA/HbA1c: Glycated albumin/glycated hemoglobin.

Table 4 Aspartate aminotransferase-to-platelet ratio index for the detection of significant liver fibrosis (F2-F4)

	F2-F4 (%)	F0-F1 (%)		F2-F4 (%)	F0-F1 (%)
APRI > 0.5	68/81 (84.0)	32/61 (52.5)	APRI > 1.5	21/81 (25.9)	6/61 (9.8)
APRI ≤ 0.5	13/81 (16.0)	29/61 (47.5)	APRI ≤ 1.5	60/81 (74.1)	55/61 (90.2)

APRI: Aspartate aminotransferase-to-platelet ratio index.

Table 5 Combination of aspartate aminotransferase-to-platelet ratio index and glycated albumin/glycated hemoglobin ratio for the detection of significant liver fibrosis (F2-F4)

	F2-F4 (%)	F0-F1 (%)		F2-F4 (%)	F0-F1 (%)
APRI > 1.5 or GA/HbA1c > 3.0	43/81 (53.1)	18/61 (29.5)	APRI > 1.5 or GA/HbA1c > 3.2	34/81 (42.0)	10/61 (16.4)
Others	38/81 (46.9)	43/61 (70.5)	Others	47/81 (58.0)	51/61 (83.6)

GA/HbA1c: Glycated albumin/glycated hemoglobin; APRI: Aspartate aminotransferase-to-platelet ratio index.